Patient-controlled health data startup Novellia announced an $18 million Series A funding round, bringing its total funding to $28 million. The company is scaling a platform that allows patients to consolidate their medical records and choose to share them with drug companies for research. Novellia also launched a new patient-facing mobile app.
Novellia positions itself as the only real-world data company built entirely on patient-contributed information, differentiating itself from third-party data brokers that assemble datasets from insurance claims and hospital records. The current model, Novellia argues, leaves patients out of a market worth over $50 billion annually.
The platform aggregates up to 20 years of medical history from disparate systems across the U.S. in under 30 seconds. It is especially aimed at individuals managing serious or complex conditions. Once records are consolidated, Novellia uses natural language processing to extract structured signals from unstructured clinical text, including physician notes and lab reports. The de-identified data is then used by pharmaceutical companies for research.
Novellia counts several top-tier pharmaceutical companies among its customers, with multiyear, seven-figure contracts signed since the Series A closed. The funding round was led by Spark Capital, with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV.